DK3250575T3 - Tosylatsalt af n-[3-[(4ar,7as)-2-amino-6-(5-fluorpyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluor-phenyl]-5-methoxy-pyrazin-2-carboxamid - Google Patents

Tosylatsalt af n-[3-[(4ar,7as)-2-amino-6-(5-fluorpyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluor-phenyl]-5-methoxy-pyrazin-2-carboxamid Download PDF

Info

Publication number
DK3250575T3
DK3250575T3 DK16702654.1T DK16702654T DK3250575T3 DK 3250575 T3 DK3250575 T3 DK 3250575T3 DK 16702654 T DK16702654 T DK 16702654T DK 3250575 T3 DK3250575 T3 DK 3250575T3
Authority
DK
Denmark
Prior art keywords
fluorpyrimidin
tetrahydropyrrolo
thiazin
pyrazin
carboxamide
Prior art date
Application number
DK16702654.1T
Other languages
English (en)
Inventor
David Andrew Coates
Craig Daniel Wolfangel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3250575T3 publication Critical patent/DK3250575T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK16702654.1T 2015-01-30 2016-01-22 Tosylatsalt af n-[3-[(4ar,7as)-2-amino-6-(5-fluorpyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluor-phenyl]-5-methoxy-pyrazin-2-carboxamid DK3250575T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562109733P 2015-01-30 2015-01-30
PCT/US2016/014423 WO2016122968A1 (en) 2015-01-30 2016-01-22 Tosylate salt of n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide

Publications (1)

Publication Number Publication Date
DK3250575T3 true DK3250575T3 (da) 2020-01-20

Family

ID=55275232

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16702654.1T DK3250575T3 (da) 2015-01-30 2016-01-22 Tosylatsalt af n-[3-[(4ar,7as)-2-amino-6-(5-fluorpyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluor-phenyl]-5-methoxy-pyrazin-2-carboxamid

Country Status (41)

Country Link
US (1) US10080758B2 (da)
EP (1) EP3250575B1 (da)
JP (2) JP6723250B2 (da)
KR (1) KR101950129B1 (da)
CN (1) CN107108657B (da)
AR (1) AR103406A1 (da)
AU (1) AU2016211827B2 (da)
BR (1) BR112017012149A2 (da)
CA (1) CA2969475C (da)
CL (1) CL2017001899A1 (da)
CO (1) CO2017007810A2 (da)
CR (1) CR20170287A (da)
CY (1) CY1122548T1 (da)
DK (1) DK3250575T3 (da)
DO (1) DOP2017000159A (da)
EA (1) EA031330B1 (da)
EC (1) ECSP17048768A (da)
ES (1) ES2768782T3 (da)
GT (1) GT201700166A (da)
HR (1) HRP20192240T1 (da)
HU (1) HUE048029T2 (da)
IL (1) IL252754A0 (da)
LT (1) LT3250575T (da)
MA (1) MA41420B1 (da)
MD (1) MD3250575T2 (da)
ME (1) ME03581B (da)
MX (1) MX2017009713A (da)
NZ (1) NZ732381A (da)
PE (1) PE20171333A1 (da)
PH (1) PH12017501356A1 (da)
PL (1) PL3250575T3 (da)
PT (1) PT3250575T (da)
RS (1) RS59730B1 (da)
SG (1) SG11201706038PA (da)
SI (1) SI3250575T1 (da)
SV (1) SV2017005478A (da)
TN (1) TN2017000332A1 (da)
TW (1) TWI574969B (da)
UA (1) UA119581C2 (da)
WO (1) WO2016122968A1 (da)
ZA (1) ZA201703937B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT401651B (de) * 1994-06-14 1996-11-25 Biochemie Gmbh 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4-
CN101939306A (zh) * 2007-12-07 2011-01-05 美国辉瑞有限公司 反式-n-异丁基-3-氟-3-[3-氟-4-(吡咯烷-1-基-甲基)-苯基]环丁烷甲酰胺的甲苯磺酸盐
PL2233474T3 (pl) * 2008-01-18 2015-12-31 Eisai R&D Man Co Ltd Skondensowana pochodna aminodihydrotiazyny
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
TWI570127B (zh) * 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato

Also Published As

Publication number Publication date
SI3250575T1 (sl) 2019-12-31
ECSP17048768A (es) 2017-11-30
TW201636354A (zh) 2016-10-16
AU2016211827B2 (en) 2018-04-26
LT3250575T (lt) 2020-02-10
US10080758B2 (en) 2018-09-25
WO2016122968A1 (en) 2016-08-04
RS59730B1 (sr) 2020-02-28
CN107108657A (zh) 2017-08-29
CA2969475A1 (en) 2016-08-04
AU2016211827A1 (en) 2017-06-22
JP6723250B2 (ja) 2020-07-15
AR103406A1 (es) 2017-05-10
DOP2017000159A (es) 2017-07-31
PT3250575T (pt) 2020-01-16
PE20171333A1 (es) 2017-09-13
MX2017009713A (es) 2017-11-17
EA201791229A1 (ru) 2017-11-30
CY1122548T1 (el) 2021-01-27
SV2017005478A (es) 2018-02-09
CN107108657B (zh) 2021-10-08
MA41420B1 (fr) 2020-02-28
KR20170097782A (ko) 2017-08-28
MD3250575T2 (ro) 2020-03-31
NZ732381A (en) 2018-05-25
IL252754A0 (en) 2017-08-31
CO2017007810A2 (es) 2017-10-20
HUE048029T2 (hu) 2020-05-28
PH12017501356A1 (en) 2017-12-11
EP3250575B1 (en) 2019-11-20
TWI574969B (zh) 2017-03-21
ES2768782T3 (es) 2020-06-23
JP2019142902A (ja) 2019-08-29
SG11201706038PA (en) 2017-08-30
ME03581B (me) 2020-07-20
CA2969475C (en) 2019-06-18
CL2017001899A1 (es) 2018-03-23
EA031330B1 (ru) 2018-12-28
PL3250575T3 (pl) 2020-06-01
UA119581C2 (uk) 2019-07-10
CR20170287A (es) 2017-07-20
HRP20192240T1 (hr) 2020-03-06
BR112017012149A2 (pt) 2018-01-02
JP2018503666A (ja) 2018-02-08
TN2017000332A1 (en) 2019-01-16
EP3250575A1 (en) 2017-12-06
KR101950129B1 (ko) 2019-02-19
US20170368071A1 (en) 2017-12-28
ZA201703937B (en) 2019-01-30
GT201700166A (es) 2018-11-23

Similar Documents

Publication Publication Date Title
IL287331A (en) Use of 3-isoxazolidinones compounds as selective herbicides
EP3442586A4 (en) STABLE PARENTERAL NIMOPIDINE FORMULATION
DK3798222T3 (da) Krystallinsk form af den frie base af lorlatinib
PT3457851T (pt) Derivados de sobetiroma
DK3191406T3 (da) Fremgangsmåde til fremstilling af aluminiumchloridderivater
DK3390407T3 (da) Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
MA41542A (fr) Nouveaux dérivés de n-acyl-arylsulfonamide utilisés en tant qu'inhibiteurs d'aminoacyl-arnt synthétase
DK3418273T3 (da) Derivater af flavagliner
MA41842A (fr) Nouveaux procédés de sélection d'épitope
DK3390412T3 (da) Vandopløselige derivater af 3,5-diphenyl-diazolforbindelser
EP3364078A4 (en) SEAL RING
DK3430004T3 (da) Faststofformer af nilotinibsalte
DK3397621T3 (da) Fremgangsmåde til fremstilling af 1,1,3-trioxo-1,2-benzothiazol-6-carboxamid
DK3274331T3 (da) Fremstilling af 4,5,6,7-tetrahydroisozaxolo[5,4-c]pyridin-3-ol
IL272670A (en) Preparation of micro-electrodes
DK3250575T3 (da) Tosylatsalt af n-[3-[(4ar,7as)-2-amino-6-(5-fluorpyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluor-phenyl]-5-methoxy-pyrazin-2-carboxamid
PT3556349T (pt) Preparação de líquido parentérico compreendendo composto carbamato
DK3515454T3 (da) Krystallinsk polymorf form af 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-[1,2]oxaphosphinan
EP3387469A4 (en) ELEKTROFAZIENBESTIMMUNG
DK3325489T3 (da) Asymmetrisk fremgangsmåde til fremstilling af thien-indolderivater
DK3397620T3 (da) Fremgangsmåde til fremstilling af 1,1,3-Trioxo-1,2-benzothiazol-6-carboxamid
DK3380453T3 (da) Syntese af beta-mercaptoethanol
DK3042948T3 (da) Solid dyrkningsanordning af den roterende type
DK3526327T3 (da) Mutagenisering af intracellulære nukleinsyrer
HK1241377A1 (en) Tosylate salt of n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide